Figure 5.

TOP2A and β-tubulin indices are more accurate than a similarly derived proliferation index.A) ROC analusis of TOP2A index and patient response to neoadjuvant docetaxel therapy ( p = 0.14). B) TOP2A index scores of patients who experienced pCR or had RD after neoadjuvant docetaxel chemotherapy ( p =0.14, t-test). C) The TOP2A and β-tubulin indices outperform an E2F1-derived proliferation at predicting response to neoadjuvant chemotherapy in multiple patient datasets (* p <0.05, ANOVA, Tukey’s test).

Hallett et al. BMC Medical Genomics 2012 5:16   doi:10.1186/1755-8794-5-16
Download authors' original image